Industrial quality control and regulatory compliance key points for capture probe panels

Product Positioning and Regulatory Framework

Capture probe panels can serve in the industry chain either as standalone research-use reagents or as key components of in vitro diagnostic reagents or medical devices. Different product positioning directly affects their regulatory pathways and quality system requirements. If a product is intended for clinical diagnosis, it should be managed as a medical device or in vitro diagnostic reagent in accordance with relevant regulations, involving classification determination, registration testing, clinical evaluation, and other steps; if it is intended only for research or laboratory-developed methods, it must also comply with corresponding biosafety and quality management standards. Manufacturers should clarify the intended use at the early stage of product development to avoid using research-use products directly for clinical decision-making.

In mainland China, the regulation of in vitro diagnostic reagents and medical devices follows the principle of risk classification. The specific management attributes and registration pathway of capture probe panels need to be determined on a case-by-case basis according to product composition, intended use, and the supporting detection system. It is recommended that companies communicate with regulatory authorities or professional consultants as early as possible to obtain targeted compliance advice.

Design and Development and Design Lock

During the design and development stage, elements such as the target region list, probe sequences, concentration ratios, buffer system, reaction temperature, and washing conditions should be systematically organized to form complete design documentation. Design lock means that after verification is completed, key parameters must not be changed arbitrarily. If panel content needs to be adjusted due to reference genome updates or changes in clinical needs, a change control process should be initiated to evaluate the impact of the change on capture efficiency, coverage uniformity, and analytical performance, and necessary revalidation should be carried out.

Design verification usually includes two parts: bioinformatics assessment and experimental verification. At the bioinformatics level, probe uniqueness, target coverage, and potential homologous interference can be evaluated; at the experimental level, reference cell lines, residual clinical samples, or synthetic reference materials are used to verify target region coverage, uniformity, and the ability to detect known variants. Verification reports should be retained and used as part of the registration dossier.

Key Quality Control Points in the Production Process

The production of capture probe panels involves multiple steps such as oligonucleotide synthesis, modification, purification, quantification, mixing, aliquoting, and storage. Each step may introduce variation, so key quality control points need to be established. For example, the synthesis step should focus on sequence correctness and the proportion of full-length products; the purification step should focus on residual impurities and the integrity of modified groups; the mixing step should focus on the accuracy and uniformity of each probe added; the aliquoting step should focus on fill volume variation and sealing integrity.

Common release testing may include appearance, concentration, purity, pH, sterility or microbial limits (if applicable), and functional testing. Functional testing usually uses standard reference samples for hybridization capture to check whether target region coverage and uniformity are within preset ranges. Batch-to-batch consistency is one of the core objectives of quality management. It is recommended to use the same batch of reference materials as a control, accumulate batch-to-batch data, and set reasonable acceptance criteria.

Raw material supplier audit and evaluation.

Calibration and maintenance records of key equipment.

Monitoring of ambient temperature, humidity, and cleanliness.

Retention sample management for intermediates and finished products.

Stability and Shipping Validation

Stability studies are the basis for confirming that capture probe panels maintain performance under labeled storage conditions. They generally include long-term stability, accelerated stability, and post-opening stability. Common storage conditions may be low-temperature freezing or refrigeration, and the specific conditions need to be determined based on formulation and validation data. Shipping validation needs to simulate temperature fluctuations in actual logistics and evaluate the impact of short-term exposure to high temperatures or freeze-thaw cycles on probe activity.

Stability studies should select indicators that can reflect key performance, such as target region coverage depth, uniformity, and probe integrity. Study protocols and results should be documented in reports to provide a basis for product shelf life and shipping conditions. For custom panels or products with frequently updated designs, companies may establish platform-based stability data, but they need to evaluate the impact of design changes on stability.

General Approach to Registration and Clinical Evaluation

For detection systems related to capture probe panels managed as in vitro diagnostic reagents or medical devices, the registration dossier usually includes product technical requirements, analytical performance evaluation, stability studies, reference intervals (if applicable), and clinical evaluation. Analytical performance may cover dimensions such as precision, accuracy, analytical sensitivity, analytical specificity, and anti-interference capability. Clinical evaluation needs to be carried out around the intended use and follow relevant guiding principles.

What should be avoided is equating analytical performance data directly with clinical effectiveness. Clinical evaluation should be designed by qualified personnel or institutions, taking into account the applicable population, sample types, and disease prevalence characteristics. Any promotional materials should avoid false or exaggerated statements and objectively describe the product's uses and limitations.

Supply Chain and Post-Market Surveillance

In the post-market stage, companies should continuously monitor the performance of capture probe panels in real-world use environments.Establish a batch traceability system to ensure a clear correspondence between raw materials, intermediates, and finished products. In the event of a complaint or adverse event, timely investigation and corrective and preventive actions should be taken. If critical raw materials or process changes are involved, the impact on product performance should be evaluated, and regulatory authorities should be notified when necessary.

Supply chain management includes supplier audits, incoming inspections, and inventory management. The quality stability of raw materials for probe synthesis directly affects finished product quality. It is recommended to sign quality agreements with key suppliers and conduct regular audits. By improving the post-market surveillance system, companies can reduce compliance risks and accumulate data for continuous product improvement.